Apraglutide (FE 203799)

Catalog No.E0021

For research use only.

Apraglutide (FE 203799) is a potent and highly selective GLP-2 agonist with EC50s of 0.03 nM and 0.07 nM for hGLP-2 Receptor and rGLP-2 Receptor, respectively.

Apraglutide (FE 203799) Chemical Structure

CAS No. 1295353-98-8

Purity & Quality Control

Choose Selective Glucagon Receptor Inhibitors

Biological Activity

Description

Apraglutide (FE 203799) is a potent and highly selective GLP-2 agonist with EC50s of 0.03 nM and 0.07 nM for hGLP-2 Receptor and rGLP-2 Receptor, respectively.

Targets
hGLP-2 Receptor [1] rGLP-2 Receptor [1]
0.03 nM(EC50) 0.07 nM(EC50)

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 3765.25
Formula

C172H263N43O52

CAS No. 1295353-98-8
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05415410 Recruiting Drug: Apraglutide GVHD VectivBio AG May 25 2022 Phase 2
NCT04964986 Active not recruiting Drug: Apraglutide Short Bowel Syndrome VectivBio AG June 14 2021 Phase 2
NCT04627025 Recruiting Drug: apraglutide Short Bowel Syndrome VectivBio AG January 26 2021 Phase 3
NCT03417765 Withdrawn Drug: FE 203799 Lymphoma Non-Hodgkin''s Adult|Lymphoma Hodgkin''s Adult GlyPharma Therapeutics|VectivBio AG September 1 2018 Phase 1|Phase 2
NCT03408132 Completed Drug: FE203799 SBS - Short Bowel Syndrome GlyPharma Therapeutics|VectivBio AG May 2 2018 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-11-29)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Apraglutide (FE 203799) | Apraglutide (FE 203799) supplier | purchase Apraglutide (FE 203799) | Apraglutide (FE 203799) cost | Apraglutide (FE 203799) manufacturer | order Apraglutide (FE 203799) | Apraglutide (FE 203799) distributor